---
title: "Hims & Hers Shares Rebound Friday: What's Driving the Move?"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294548547.md"
description: "Hims & Hers Health (HIMS) shares rose 2.44% on Friday, rebounding from technical support despite regulatory headwinds. The FTC is reportedly preparing a lawsuit alleging unlawful data sharing with advertisers like Meta and Snap, which HIMS denies as baseless. Trading occurs near the 100-day SMA, with $30.00 identified as key resistance needed to shift the near-term trend bullish."
datetime: "2026-07-31T18:41:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294548547.md)
  - [en](https://longbridge.com/en/news/294548547.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294548547.md)
---

# Hims & Hers Shares Rebound Friday: What's Driving the Move?

**Hims & Hers Health Inc**. (NYSE:HIMS) shares are trading higher on Friday as traders continue to weigh fresh regulatory scrutiny against a generally risk-on tape. Here’s what investors need to know.

-   Hims & Hers Health shares are trending higher. Why is HIMS stock trading higher?

## What Is Driving Hims & Hers Health’s Stock Today?

The FTC is reportedly preparing a lawsuit alleging Hims & Hers unlawfully shared sensitive customer health data with online advertisers and used deceptive billing and cancellation practices. The report specifically names **Meta Platforms** and **Snap Inc** as ad firms tied to the alleged data flow via tracking technologies.

In response, the company said the case ignores evidence it provided during a nearly three-year investigation and that it plans to vigorously defend against what it called "baseless claims."

Hims is also navigating sentiment headwinds into earnings after **Jim Cramer** called the stock "controversial" and said he’d rather own **Eli Lilly**.

## HIMS Stock: Critical Levels To Watch

Friday’s bounce is happening from a technically important area: the stock is now just 0.7% above its 100-day SMA ($27.51), while still trading 14.9% below its 20-day SMA ($32.54) and 9.8% below its 50-day SMA ($30.72). That mix usually reads as "trying to base," but with overhead supply still close enough to cap rallies.

Momentum is the bigger issue right now: MACD is below its signal line and the histogram is negative, which points to upside pressure cooling unless buyers can reassert control. Even with the bullish moving-average backdrop (the golden cross in July), the stock still needs to reclaim the $30.00 area to shift the near-term trend back toward the bulls.

-   **Key Resistance**: $30.00 — a round-number ceiling that also sits near the 50-day SMA/EMA zone where rebounds can stall

## HIMS Stock Price Action on Friday

**HIMS Stock Price Activity:** Hims & Hers Health shares were up 2.44% at $27.70 at the time of publication on Friday, according to Benzinga Pro data.

**Read Also: Moleculin Biotech Stock Is Sinking Friday: What's Going On?**

_Image: Shutterstock_

### Related Stocks

- [HIMS.US](https://longbridge.com/en/quote/HIMS.US.md)
- [HIMZ.US](https://longbridge.com/en/quote/HIMZ.US.md)
- [HIMY.US](https://longbridge.com/en/quote/HIMY.US.md)
- [SNAP.US](https://longbridge.com/en/quote/SNAP.US.md)
- [HIYY.US](https://longbridge.com/en/quote/HIYY.US.md)
- [META.US](https://longbridge.com/en/quote/META.US.md)
- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)
- [MBRX.US](https://longbridge.com/en/quote/MBRX.US.md)

## Related News & Research

- [HIMS Stock in Focus as FTC Lawsuit Takes Aim at Hims & Hers Business Practices](https://longbridge.com/en/news/294383717.md)
- [HIMS Stock Sinks as FDA Gives Hims & Hers Peptide the Cold Shoulder](https://longbridge.com/en/news/293791898.md)
- [Hims & Hers Stock Jumps on Vow to 'Vigorously' Defend Against FTC's 'Baseless Claims'](https://longbridge.com/en/news/294379271.md)
- [Hims & Hers Responds to FTC Lawsuit | HIMS Stock News](https://longbridge.com/en/news/294240928.md)
- [Hims & Hers stock plunges after FTC sues over alleged privacy violations](https://longbridge.com/en/news/294240792.md)